JP7870987B2 - 環状gmp-amp合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用 - Google Patents
環状gmp-amp合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用Info
- Publication number
- JP7870987B2 JP7870987B2 JP2025536183A JP2025536183A JP7870987B2 JP 7870987 B2 JP7870987 B2 JP 7870987B2 JP 2025536183 A JP2025536183 A JP 2025536183A JP 2025536183 A JP2025536183 A JP 2025536183A JP 7870987 B2 JP7870987 B2 JP 7870987B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- compound
- formula
- alkyl
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263433987P | 2022-12-20 | 2022-12-20 | |
| US63/433,987 | 2022-12-20 | ||
| US202363501320P | 2023-05-10 | 2023-05-10 | |
| US63/501,320 | 2023-05-10 | ||
| PCT/US2023/084787 WO2024137607A1 (en) | 2022-12-20 | 2023-12-19 | Thiadiazole derivatives as inhibitors of cyclic gmp-amp synthase and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2026501225A JP2026501225A (ja) | 2026-01-14 |
| JP2026501225A5 JP2026501225A5 (cg-RX-API-DMAC7.html) | 2026-01-27 |
| JP7870987B2 true JP7870987B2 (ja) | 2026-06-08 |
Family
ID=89768384
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025536183A Active JP7870987B2 (ja) | 2022-12-20 | 2023-12-19 | 環状gmp-amp合成酵素の阻害剤としてのチアジアゾール誘導体及びその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240270740A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4638446A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7870987B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250131845A (cg-RX-API-DMAC7.html) |
| CN (1) | CN120530109A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023408761A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2025001819A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2025007987A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL321525A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2025007158A (cg-RX-API-DMAC7.html) |
| PE (1) | PE20251918A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202434205A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2024137607A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026077404A1 (zh) * | 2024-10-10 | 2026-04-16 | 北京知维拓医药科技有限公司 | 一种杂环类化合物及其用途 |
| WO2026158338A1 (zh) * | 2025-01-22 | 2026-07-30 | 北京知维拓医药科技有限公司 | 一种杂环类化合物及其用途 |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019055750A1 (en) | 2017-09-15 | 2019-03-21 | Aduro Biotech, Inc. | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF |
| JP2019510787A (ja) | 2016-04-05 | 2019-04-18 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
| WO2021233852A1 (en) | 2020-05-20 | 2021-11-25 | F. Hoffmann-La Roche Ag | Cgas inhibiting triazolopyrimidone derivatives |
| WO2022137085A1 (en) | 2020-12-22 | 2022-06-30 | Novartis Ag | Indole derivatives useful in treating conditions associated with cgas |
| WO2022137082A1 (en) | 2020-12-22 | 2022-06-30 | Novartis Ag | Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas |
| CN115160279A (zh) | 2022-07-27 | 2022-10-11 | 中国药科大学 | 苯并吡喃酮类化合物、药物组合物和应用 |
| JP2024542128A (ja) | 2021-11-08 | 2024-11-13 | ベンタス・セラピューティクス・ユー・エス・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| JP2016506408A (ja) | 2012-12-19 | 2016-03-03 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 哺乳動物の環状ジヌクレオチドシグナル伝達経路の薬学的標的化 |
| MX2020008237A (es) | 2018-02-05 | 2020-09-25 | Univ Rockefeller | Inhibidores de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol de cgas para tratar enfermedades autoinflamatorias. |
| WO2020072492A1 (en) * | 2018-10-02 | 2020-04-09 | Baruch S. Blumberg Institute | Benzamide derivatives as cgas-sting pathway agonists |
-
2023
- 2023-12-19 EP EP23848029.7A patent/EP4638446A1/en active Pending
- 2023-12-19 KR KR1020257024220A patent/KR20250131845A/ko active Pending
- 2023-12-19 TW TW112149428A patent/TW202434205A/zh unknown
- 2023-12-19 PE PE2025001310A patent/PE20251918A1/es unknown
- 2023-12-19 AU AU2023408761A patent/AU2023408761A1/en active Pending
- 2023-12-19 WO PCT/US2023/084787 patent/WO2024137607A1/en not_active Ceased
- 2023-12-19 CN CN202380091713.0A patent/CN120530109A/zh active Pending
- 2023-12-19 US US18/544,945 patent/US20240270740A1/en active Pending
- 2023-12-19 IL IL321525A patent/IL321525A/en unknown
- 2023-12-19 JP JP2025536183A patent/JP7870987B2/ja active Active
-
2025
- 2025-06-13 CO CONC2025/0007987A patent/CO2025007987A2/es unknown
- 2025-06-18 MX MX2025007158A patent/MX2025007158A/es unknown
- 2025-06-18 CL CL2025001819A patent/CL2025001819A1/es unknown
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019510787A (ja) | 2016-04-05 | 2019-04-18 | イミューン センサー リミテッド ライアビリティ カンパニー | cGASアンタゴニスト化合物 |
| WO2019055750A1 (en) | 2017-09-15 | 2019-03-21 | Aduro Biotech, Inc. | PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF |
| WO2021233852A1 (en) | 2020-05-20 | 2021-11-25 | F. Hoffmann-La Roche Ag | Cgas inhibiting triazolopyrimidone derivatives |
| WO2022137085A1 (en) | 2020-12-22 | 2022-06-30 | Novartis Ag | Indole derivatives useful in treating conditions associated with cgas |
| WO2022137082A1 (en) | 2020-12-22 | 2022-06-30 | Novartis Ag | Pyrrolo[3,2-b]pyridine derivatives useful in treating conditions associated with cgas |
| JP2024542128A (ja) | 2021-11-08 | 2024-11-13 | ベンタス・セラピューティクス・ユー・エス・インコーポレイテッド | ヘテロ環式化合物およびその使用 |
| CN115160279A (zh) | 2022-07-27 | 2022-10-11 | 中国药科大学 | 苯并吡喃酮类化合物、药物组合物和应用 |
Non-Patent Citations (2)
| Title |
|---|
| LAMA, Lodoe et al.,"Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression",Nature Communications,2019年05月21日,Vol. 10,No. 1,DOI: 10.1038/s41467-019-08620-4 |
| ZHAO, Wenfeng et al.,"In Silico Screening-Based Discovery of Novel Inhibitors of Human Cyclic GMP-AMP Synthase: A Cross-Validation Study of Molecular Docking and Experimental Testing",Journal of Chemical Information and Modeling,2020年05月27日,Vol. 60,No. 6,p. 3265-3276,DOI: 10.1021/acs.jcim.0c00171 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023408761A1 (en) | 2025-06-19 |
| IL321525A (en) | 2025-08-01 |
| PE20251918A1 (es) | 2025-08-05 |
| US20240270740A1 (en) | 2024-08-15 |
| CO2025007987A2 (es) | 2025-09-08 |
| TW202434205A (zh) | 2024-09-01 |
| EP4638446A1 (en) | 2025-10-29 |
| KR20250131845A (ko) | 2025-09-03 |
| MX2025007158A (es) | 2025-07-01 |
| CN120530109A (zh) | 2025-08-22 |
| WO2024137607A1 (en) | 2024-06-27 |
| CL2025001819A1 (es) | 2025-09-26 |
| JP2026501225A (ja) | 2026-01-14 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20260119 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20260119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260210 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260217 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260421 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260520 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7870987 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |